2,4-Diamino quinazoline and pyridopyrimidine ester derivatives as dihydrofolate reductase inhibitors
申请人:Hallberg Anders
公开号:US20060111376A1
公开(公告)日:2006-05-25
The invention provides novel compounds or the formula II: wherein R
1
, R
2
, R
3
and R
4
are independently hydrogen of a group that liberates the free amine in vivo, for example —CO-alkyl, preferably —CO—C
1
-C
3
alkyl or pivalate; or —COhaloalkyl, preferably —CO—C
1
-C
3
haloalkyl, most preferably —CO—C
1
-C
3
chloroalkyl; wherein W is: and @ denotes the points of attachment and wherein the ester can be located in either direction; wherein n and m are independently 0-5; wherein one but not both or X and Y can be nitrogen, or X is C-A and/or Y is C—B; wherein A and B are independently selected from hydrogen, alkyl optionally substituted with a halogen, an electron donor group such as amino, alkylamino, dialkylamino or hydroxy, or an electron acceptor group such as nitro, cyano. trihaloalkyl or amido, alkoxy or halogen; and pharmacologically acceptable salts thereof. Provided that when R
1
to R
4
are hydrogen, both X and Y are C—H, n is 1 and —(CH
2
)
n
— is attached to the bridging oxygen of the ester group W, then m cannot be 0 or 1.
本发明提供了新型化合物或式 II: 其中 R
1
, R
2
, R
3
和 R
4
是独立的氢或可在体内释放游离胺的基团,例如 -CO-烷基,最好是 -CO-C
1
-C
3
烷基或特戊酸烷基;或-CO-卤代烷基,最好是-CO-C 1 -C 3
1
-C
3
卤代烷基,最优选-CO-C 1 -C 3
1
-C
3
其中 W 为:,@ 表示连接点,酯可以位于任一方向;其中 n 和 m 独立地为 0-5;其中 X 和 Y 可以有一个(但不是两个)为氮,或 X 为 C-A 和/或 Y 为 C-B;其中 A 和 B 独立地选自氢、任选被卤素取代的烷基、电子供体基团如氨基、烷基氨基、二烷基氨基或羟基,或电子受体基团如硝基、氰基、三卤代烷基或氨基、烷氧基或卤素;以及它们的药理学可接受盐。三卤代烷基或氨基、烷氧基或卤素;及其药理学上可接受的盐类。但当 R
1
至 R
4
为氢、X 和 Y 均为 C-H、n 为 1 且-(CH
2
)
n
- 与酯基 W 的桥接氧相连,则 m 不能为 0 或 1。